Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

22/07/2026 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.01%, closing at 52218.58 points; the Nasdaq Composite dropped by 0.57%, closing at 25690.9 points; the S&P 500 Index dropped by 0.14%, closing at 7498.96 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

QumulusAI, Inc.: Overnight gain 34.5%, Surges Amid NVIDIA Partnership Approval and Massive GPU Order Announcement

**QumulusAI, Inc. Offers GPU-Accelerated Infrastructure Solutions Targeting Underserved SMB AI Market** QumulusAI, Inc., incorporated in the State of Georgia on December 9, 2022, is a specialized provider of GPU-based rapid deployment solutions purpose-built for artificial intelligence applications. The Company primarily serves small- and medium-sized business ("SMB") clients, addressing a critical service gap left by large-scale hyperscale cloud providers in this underserved market segment. The Company's core business operations encompass the delivery of flexible, competitively priced, and fully customizable infrastructure solutions tailored to the distinct requirements of machine learning teams, AI infrastructure startups, and research institutions. In addition, QumulusAI, Inc. is positioned to accommodate the supplemental compute capacity and long-term deployment needs of larger enterprise clients seeking scalable alternatives to conventional hyperscale offerings.

**QumulusAI, Inc. (QMLS) Surges 34.5% Overnight on NVIDIA Partnership and Major GPU Order** Shares of QumulusAI, Inc. (QMLS) rallied 34.5% overnight, driven by two significant catalysts. The company announced its acceptance into NVIDIA's Partner Network (NPN) and attainment of NVIDIA Cloud Partner (NCP) status, reinforcing market confidence in its technological capabilities and commercial credibility. Concurrently, QumulusAI, Inc. (QMLS) disclosed an order for 1,632 NVIDIA Blackwell B300 GPUs deployed across 204 HGX B300 systems, providing critical computing infrastructure to support previously contracted inference service agreements exceeding $124 million over a three-year term. The convergence of these dual positive developments, combined with a technical rebound from the stock's year-to-date decline of approximately 75.9%, amplified buying momentum and propelled the sharp overnight price appreciation.

Finward Bancorp: Overnight gain 22.8%, Surges After First Financial Bancorp Announces All-Stock Acquisition Deal

**Finward Bancorp: Corporate Profile** Finward Bancorp was incorporated in the State of Indiana on January 31, 1994. The Company operates through its wholly owned banking subsidiary, Peoples Bank, which holds a commercial banking charter issued by the State of Indiana. The institution maintains a well-established market presence across northwestern Indiana and Illinois, with core business operations encompassing deposit-taking, residential mortgage lending, commercial real estate lending, construction lending, and consumer and municipal lending. Its wealth management division offers a comprehensive suite of services, including trust administration, estate planning, and investment account management. As a bank holding company, Finward Bancorp is subject to federal regulatory oversight, while its banking subsidiary operates under the dual supervisory framework of the Federal Deposit Insurance Corporation (FDIC) and the Indiana Department of Financial Institutions (IDFI). The Company is headquartered in Munster, Indiana.

**Finward Bancorp(FNWD) Surges After-Hours on Acquisition Announcement** Shares of Finward Bancorp(FNWD) posted a notable after-hours gain of 22.8%, driven by First Financial Bancorp(FFBC)'s announcement of a definitive agreement to acquire Finward Bancorp(FNWD) in an all-stock transaction valued at approximately $208 million. Under the terms of the deal, each share of Finward Bancorp(FNWD) common stock will be exchanged for 1.35 shares of First Financial Bancorp(FFBC) common stock. Upon completion, the Chicago and Northwest Indiana markets will become First Financial Bancorp(FFBC)'s second-largest market, with combined regional deposits reaching $4.1 billion. The transaction is expected to be approximately 5% accretive to FFBC's earnings per share, with tangible book value dilution of just 0.4% and an earnback period of approximately 0.6 years, reflecting compelling financial merits. Both boards have unanimously approved the deal, with closing anticipated in Q4 2026.

AirJoule Technologies Corporation Class A: Overnight gain 22.0%, Surges Amid Growing Demand for Clean Energy and Atmospheric Water Technology

**AirJoule Technologies Corporation Class A — Company Overview** AirJoule Technologies Corporation was incorporated in the State of Delaware on March 23, 2021, with a strategic focus on atmospheric renewable energy and water harvesting technologies. The Company is dedicated to delivering highly efficient and sustainable solutions across dehumidification, evaporative cooling, and atmospheric water generation applications. At the core of its value proposition is the proprietary AirJoule technology, which demonstrates a compelling competitive advantage over conventional HVAC systems by significantly reducing energy consumption, minimizing the use of harmful refrigerants, and generating substantial cost efficiencies. The technology positions AirJoule Technologies as a differentiated player in the growing market for clean energy and resource-efficient climate control solutions.

**AirJoule Technologies Corporation Class A (AIRJ) Surges 22.0% Overnight Amid Clean Energy Momentum** Shares of AirJoule Technologies Corporation Class A (AIRJ) posted a remarkable single-session gain of 22.0%, bringing year-to-date appreciation to 16.8%, reflecting sustained market confidence in the company's commercialization prospects. The rally is underpinned by growing investor recognition of the company's proprietary AirJoule technology, which operates within the atmospheric renewable energy and water harvesting sector. Compared to conventional HVAC systems, AirJoule's solution delivers meaningful differentiation through reduced energy consumption, minimized use of harmful refrigerants, and multi-functional capabilities encompassing dehumidification, evaporative cooling, and atmospheric water generation. Against a backdrop of accelerating global carbon neutrality commitments and intensifying water scarcity concerns, capital flows into the clean energy segment have increased notably. The overnight surge reflects a confluence of multiple positive catalysts resonating simultaneously within this high-growth niche.

Super Micro Computer, Inc.: Overnight gain 19.8%, Surges Amid Record Backlog, Margin Expansion, and Improved Pricing Power

**Super Micro Computer, Inc. – Company Overview** Super Micro Computer, Inc. was incorporated in the State of California in September 1993 and subsequently redomiciled in the State of Delaware in March 2007. Headquartered in Silicon Valley, the Company is principally engaged in the research, development, and supply of accelerated computing platforms, offering a comprehensive portfolio of products that encompasses high-performance servers, storage systems, modular blade servers, workstations, and full rack-scale solutions. The Company's offerings serve a broad range of end markets, including enterprise data centers, cloud computing, artificial intelligence, 5G infrastructure, and edge computing. In addition to its core hardware offerings, Super Micro Computer provides networking equipment, server subsystems, and management and security software, complemented by a global support and services infrastructure designed to assist customers in the installation, upgrade, and maintenance of their computing environments. Leveraging an extensive array of server form factors and configuration options, the Company delivers highly flexible and customizable solutions tailored to diverse customer requirements. Its system architecture is engineered to achieve elevated standards of reliability, configurability, and scalability, positioning the Company as a differentiated provider within the competitive accelerated computing landscape.

**Super Micro Computer, Inc. (SMCI) Surges on Robust Margin Outlook and Record Backlog** Shares of Super Micro Computer, Inc. (SMCI) rallied sharply after the company issued a preliminary outlook for fiscal Q4 2026, projecting GAAP and non-GAAP gross margins of 15% to 17% — nearly double its prior guidance of 8.2% to 8.4%. The significant margin expansion was attributed to an optimized customer mix and a higher proportion of premium, high-margin product sales. Additionally, new orders exceeded $60 billion in fiscal Q4, driving the company's backlog to a record high and providing strong revenue visibility for coming quarters. Wedbush analysts noted that persistent shortages of critical components, including NVIDIA GPUs, have enhanced SMCI's pricing power and materially improved earnings quality. The positive developments also lifted shares of sector peers, including Dell Technologies and Hewlett Packard Enterprise, reflecting broader optimism across the AI infrastructure supply chain.

Oatly Group AB: Overnight gain 19.1%, Surges Amid Strong Quarterly Results, Raised Guidance, and Analyst Endorsement

**Oatly Group AB: A Pioneer in Plant-Based Innovation with Over Three Decades of Oat Expertise** Oatly Group AB was incorporated in Sweden in October 2016, drawing upon more than 30 years of specialized expertise in oat-based research and development. The company is dedicated to creating sustainable and health-oriented oat-based products, continuously expanding its product portfolio through ongoing technological innovation. At the core of Oatly's mission is the development of nutritious and palatable plant-based beverages, strategically positioned to capitalize on the accelerating consumer shift from animal-derived to plant-based food products, while actively addressing the global challenge of climate change. To date, Oatly has successfully diversified its product offerings across a broad spectrum of dairy alternative categories, encompassing oat milk, ice cream, yogurt, cooking creams, spreads, and ready-to-drink beverages, reinforcing its standing as a leading innovator in the rapidly growing plant-based food and beverage sector.

**Oatly Group AB (OTLY) Surges 19.1% on Strong Q2 Beat and Raised Guidance** Shares of Oatly Group AB (OTLY) rallied sharply, gaining 19.1% in a single session, driven by a confluence of positive catalysts. The company reported fiscal Q2 2026 financial results that broadly exceeded market expectations, with a loss per share of $(0.99), surpassing the consensus estimate of $(1.06) and narrowing 46.77% year-over-year. Quarterly revenue reached $240 million, beating expectations by 9.65% and rising 15.23% year-over-year. Additionally, Oatly Group AB (OTLY) significantly raised its full-year revenue guidance to a range of $908.8 million to $925.6 million, up approximately 4.9% from the prior outlook of $866.7 million to $883.6 million, closely aligning with market consensus. Barclays analyst Andrew Lazar also reaffirmed an "Overweight" rating on the stock, with multiple positive factors converging to fuel the robust single-day advance.

Arrowhead Pharmaceuticals, Inc.: Overnight gain 19.0%, Surges After JPMorgan Raises Price Target, Maintains Overweight Rating

**Arrowhead Pharmaceuticals, Inc.: Company Profile** Arrowhead Pharmaceuticals, Inc. was originally incorporated in the state of South Dakota in 1989 before subsequently redomiciling to the state of Delaware. The Company is dedicated to the discovery and development of innovative therapeutics targeting intractable diseases through gene-silencing mechanisms. Leveraging a diversified RNA chemistry platform in conjunction with highly efficient delivery technologies, Arrowhead's proprietary approach triggers RNA interference (RNAi) pathways to achieve rapid, profound, and durable knockdown of disease-associated target genes. The Company has strategically concentrated its core resources across multiple therapeutic areas, with a focused pipeline of pharmacologically active drug candidates designed to address significant unmet medical needs.

**Arrowhead Pharmaceuticals, Inc. (ARWR) Surges 19.0% Following JPMorgan Price Target Upgrade** Shares of Arrowhead Pharmaceuticals, Inc. (ARWR) posted a single-day gain of 19.0%, driven primarily by JPMorgan analyst Brian Cheng reaffirming an **Overweight** rating on the stock while raising the price target from $88 to $95. The upgrade from one of Wall Street's premier investment banks signals sustained confidence in Arrowhead Pharmaceuticals, Inc.'s (ARWR) fundamental outlook, effectively bolstering market sentiment and catalyzing concentrated institutional capital inflows. The bullish endorsement further amplifies upward price momentum, building on the stock's already robust year-to-date gain of 33.6% and a current market capitalization of approximately $12.494 billion. The institutional backing underscores capital markets' growing recognition of the intrinsic pipeline value embedded in Arrowhead Pharmaceuticals, Inc.'s (ARWR) innovative RNAi therapeutic platform.

Super Micro Computer, Inc. Depository Shs Repr 1/20th Conv Pfd Registered Shs: Overnight gain 16.7%, Surges Amid Strong SMCI Linkage and Convertible Preferred Revaluation Momentum

Company profile missing.

**Super Micro Computer, Inc. Depository Shs Repr 1/20th Conv Pfd Registered Shs (SMCIP) Surges 16.7% on Converging Catalysts** Shares of Super Micro Computer, Inc. Depository Shs Repr 1/20th Conv Pfd Registered Shs (SMCIP) posted a notable single-session gain of 16.7%, driven by multiple converging factors. As depositary shares each representing 1/20th of a convertible preferred share in Super Micro Computer, Inc. (SMCI), SMCIP maintains a high degree of correlation with the underlying common stock. Any material positive developments in SMCI directly translate into upward momentum for SMCIP. Furthermore, the convertible preferred structure introduces a non-linear price amplification effect, as rising common stock prices trigger a reassessment of conversion value. Additionally, with a modest year-to-date decline of only 0.7%, accumulated technical oversold pressure created concentrated mean-reversion momentum, ultimately propelling SMCIP's sharp intraday advance.

FORTE BIOSCIENCES INC: Overnight gain 11.6%, Surges Amid Barclays Overweight Initiation and Strong Clinical Pipeline Momentum

**FORTE BIOSCIENCES INC Advances Live Biotherapeutic Candidate FB-401 for Inflammatory Skin Conditions** Forte Biosciences, Inc. (the "Company"), a clinical-stage dermatology company, is focused on the development of its proprietary live biotherapeutic product, FB-401, targeting the treatment of inflammatory skin diseases. The Company has successfully completed Phase 1/2a clinical trials evaluating FB-401 in adult patients as well as pediatric patients aged three years and above diagnosed with atopic dermatitis. Given the robust and unmet market demand for safe and efficacious therapeutic options — particularly within the pediatric atopic dermatitis segment — the Company intends to advance FB-401 into Phase 2 clinical development, with progression anticipated in the mid-2020s. This strategic initiative underscores Forte Biosciences' commitment to addressing critical gaps in dermatological care and delivering meaningful clinical outcomes for patient populations with limited treatment alternatives.

**FORTE BIOSCIENCES INC (FBRX) Surges on Barclays Initiation with Overweight Rating** Shares of FORTE BIOSCIENCES INC (FBRX) rallied sharply after Barclays analyst Etzer Darout initiated coverage of the company with an **Overweight** rating and a price target of **$74**, sending a strongly bullish signal to the market. The authoritative institutional endorsement directly bolstered investor confidence, attracting significant capital inflows into the stock. The company focuses on inflammatory skin diseases, with its lead asset **FB-401** continuing to advance clinical progress in the treatment of atopic dermatitis, underpinning solid fundamentals. Driven by these combined catalysts, FORTE BIOSCIENCES INC (FBRX) surged **11.6%** in a single trading session, bringing its year-to-date cumulative gain to an impressive **107.7%**. The Barclays initiation is widely viewed as a pivotal endorsement, reinforcing market optimism surrounding the company's clinical pipeline and long-term growth trajectory.

Everforth, Inc.: Overnight gain 11.3%, Surges Amid Analyst Upgrade to Buy, Low Valuation Attracts Renewed Buying Interest

**Everforth, Inc. Stands as Global Leader in Life Sciences, Healthcare, and Technology Staffing Solutions** Everforth, Inc., incorporated on December 30, 1985, is a premier global provider of specialized talent solutions serving the life sciences, healthcare, and technology sectors. Distinguished by its competency-based placement methodology — which prioritizes the alignment of role requirements with candidate attributes over conventional resume screening — the Company offers a comprehensive suite of workforce solutions, including contract staffing, contract-to-permanent conversion, and direct-hire placement. The Company operates through four distinct business segments: The **Life Sciences segment** delivers both contract and permanent professional staffing services across a broad spectrum of industries, including biotechnology, pharmaceuticals, and medical devices. The **Healthcare segment** provides local and travel-based contract professionals through its Nurse Travel and Allied Health service lines. The **Physician segment** offers locum tenens and comprehensive search and consulting services on both short- and long-term bases, with operations spanning the United States, Australia, and New Zealand. The **IT & Engineering segment** focuses on delivering high-value consulting and staffing solutions within the information technology and engineering disciplines. Through its diversified operational platform, Everforth, Inc. continues to leverage deep sector expertise and a rigorous talent-matching framework to address the evolving workforce demands of its global client base.

**Everforth, Inc. (EFOR) Surges 11.3% Following Analyst Upgrade** Shares of Everforth, Inc. (EFOR) rallied sharply, closing at $18.89, up 11.3% on the session, driven primarily by a notable analyst upgrade. Truist Securities analyst Tobey Sommer raised his rating on EFOR from "Hold" to "Buy" and lifted his price target from $33 to $36, directly boosting market sentiment and catalyzing the single-day advance. The upgrade comes amid a challenging year for Everforth, Inc. (EFOR), whose shares have declined approximately 57.7% year-to-date, leaving the stock trading at a relatively depressed valuation. The combination of the bullish analyst reassessment and the stock's compressed valuation levels appears to have amplified buying interest, encouraging investors to accumulate positions. Market participants interpreted the revised price target as signaling meaningful upside potential from current levels, reinforcing renewed confidence in the company's near-term outlook.

LB Pharmaceuticals, Inc.: Overnight gain 10.9%, Surges Amid Analyst Upgrade and Accelerated Phase 3 Trial Progress

**LB Pharmaceuticals, Inc. Established as Clinical-Stage Biopharmaceutical Company Targeting Neuropsychiatric Disorders** LB Pharmaceuticals, Inc. was incorporated in September 2015 under the laws of the State of Delaware. The Company is positioned as a clinical-stage biopharmaceutical enterprise dedicated to the research and development of novel therapeutic solutions targeting schizophrenia, bipolar depression, and a broad spectrum of neuropsychiatric disorders.

**LB Pharmaceuticals, Inc. (LBRX) Surges 10.9% on Analyst Initiation and Accelerated Clinical Milestones** Shares of LB Pharmaceuticals, Inc. (LBRX) advanced 10.9% in a single session, bringing year-to-date gains to 61.0%, driven by two significant catalysts. BMO Capital analyst Malcolm Hoffman initiated coverage of LB Pharmaceuticals, Inc. (LBRX) with an "Outperform" rating and a $46 price target, providing institutional validation that bolstered investor confidence. Concurrently, LB Pharmaceuticals, Inc. (LBRX) announced that its pivotal Phase 3 schizophrenia trial, NOVA-2, is progressing ahead of schedule due to faster-than-anticipated patient enrollment. Top-line data readouts are now expected in the first half of 2027, with an FDA pre-NDA meeting targeted for the second half of 2027. The accelerated timeline meaningfully narrows the commercialization window for lead asset LB-102, with both catalysts converging to fuel the strong single-day rally.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.